A.R.T. Advisors’s Cidara Therapeutics CDTX Stock Holding History

A.R.T. Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-676	Closed	-$54K	–	1452
2018 Q1	$54K	Buy	+676	New	+$92.3K	﹤0.01%	1397
2017 Q4	–	Sell	-1,430	Closed	-$231K	–	1397
2017 Q3	$231K	Sell	1,430 -115	-7%	-$16.4K	0.01%	1090
2017 Q2	$231K	Buy	+1,545	New	+$214K	0.01%	1107
2016 Q2	–	Sell	-566	Closed	-$143K	–	1379
2016 Q1	$143K	Sell	566 -280	-33%	-$64.5K	0.01%	1221
2015 Q4	$290K	Buy	+846	New	+$254K	0.01%	1071

Other funds holding CDTX

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

A.R.T. Advisors's CDTX Position: Q2 2018 in Review

A.R.T. Advisors sold out of Cidara Therapeutics (CDTX) in Q2 2018, closing a stake of 676 shares — an estimated $54K sold.

A.R.T. Advisors first reported a position in CDTX in Q4 2015 and held it in 5 quarters. The position peaked at $290K in Q4 2015. 56 funds tracked by Wall St. Rank hold CDTX as of Q2 2018.

A.R.T. Advisors reported no remaining Cidara Therapeutics position as of Q2 2018 after selling out during the quarter.
A.R.T. Advisors sold 676 Cidara Therapeutics shares in Q2 2018, an estimated $54K.
A.R.T. Advisors first reported a position in Cidara Therapeutics in Q4 2015 and held it in 5 quarters.
A.R.T. Advisors's Cidara Therapeutics position peaked at $290K in Q4 2015.
56 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2018.

Based on A.R.T. Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.